Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report

Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibito...

ver descrição completa

Detalhes bibliográficos
Autores: Anna Carbó-Bagué, Roser Fort-Culillas, Helena Pla-Juher, Rubió Casadevall, Jordi
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10256/20509
Acesso em linha:http://hdl.handle.net/10256/20509
Access Level:acceso abierto
Palavra-chave:Anèmia hemolítica
Hemolytic anemia
id ES_f25c5002dcd66bf9c5028391e8f65b96
oai_identifier_str oai:recercat.cat:10256/20509
network_acronym_str ES
network_name_str España
repository_id_str
spelling Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case ReportAnna Carbó-BaguéRoser Fort-CulillasHelena Pla-JuherRubió Casadevall, JordiAnèmia hemolíticaHemolytic anemiaAutoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case published in the literature with the change of immunotherapy treatment to anti-CTLA4Karger Publishers2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionpeer-reviewedapplication/pdfhttp://hdl.handle.net/10256/20509http://hdl.handle.net/10256/20509Case Reports in Oncology, 2021, vol. 14, núm. 3Articles publicats (IdIBGi)Anna Carbó-Bagué Roser Fort-Culillas Helena Pla-Juher Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report Case Reports in Oncology 14 3reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglésinfo:eu-repo/semantics/altIdentifier/issn/1662-6575Reconeixement-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessoai:recercat.cat:10256/205092026-05-29T05:05:01Z
dc.title.none.fl_str_mv Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
title Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
spellingShingle Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
Anna Carbó-Bagué
Anèmia hemolítica
Hemolytic anemia
title_short Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
title_full Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
title_fullStr Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
title_full_unstemmed Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
title_sort Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
dc.creator.none.fl_str_mv Anna Carbó-Bagué
Roser Fort-Culillas
Helena Pla-Juher
Rubió Casadevall, Jordi
author Anna Carbó-Bagué
author_facet Anna Carbó-Bagué
Roser Fort-Culillas
Helena Pla-Juher
Rubió Casadevall, Jordi
author_role author
author2 Roser Fort-Culillas
Helena Pla-Juher
Rubió Casadevall, Jordi
author2_role author
author
author
dc.subject.none.fl_str_mv Anèmia hemolítica
Hemolytic anemia
topic Anèmia hemolítica
Hemolytic anemia
description Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case published in the literature with the change of immunotherapy treatment to anti-CTLA4
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
peer-reviewed
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10256/20509
http://hdl.handle.net/10256/20509
url http://hdl.handle.net/10256/20509
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1662-6575
dc.rights.none.fl_str_mv Reconeixement-NoComercial 4.0 Internacional
http://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Reconeixement-NoComercial 4.0 Internacional
http://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Karger Publishers
publisher.none.fl_str_mv Karger Publishers
dc.source.none.fl_str_mv Case Reports in Oncology, 2021, vol. 14, núm. 3
Articles publicats (IdIBGi)
Anna Carbó-Bagué Roser Fort-Culillas Helena Pla-Juher Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report Case Reports in Oncology 14 3
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424272913465344
score 15,228081

Registos relacionados